Kelly E. McCann, MD, PhD

In the closing segment, Dr. Neil Iyengar invites Dr. Kelly McCann and Dr. Alison Conlin to reflect on how emerging evidence is shaping the future management of HER2-positive early breast cancer.

Dr. Neil Iyengar concludes the case-based discussion by exploring the role of multidisciplinary care in the management of HER2-positive early breast cancer following neoadjuvant therapy.

Dr. Neil Iyengar presents a second clinical scenario focused on a patient with residual invasive disease following neoadjuvant therapy for HER2-positive early breast cancer, prompting Dr. Alison Conlin and Dr. Kelly McCann to discuss adjuvant treatment decision-making.

Dr. Neil Iyengar presents a clinical scenario involving a patient with high-risk HER2-positive early breast cancer, prompting Dr. Kelly McCann and Dr. Alison Conlin to discuss practical treatment selection in the neoadjuvant setting.

Dr. Neil Iyengar leads a discussion with Dr. Kelly McCann and Dr. Alison Conlin on balancing efficacy with safety when incorporating newer therapies into the management of HER2-positive early breast cancer.

Dr. Neil Iyengar shifts the discussion to the management of residual disease in HER2-positive early breast cancer, inviting Dr. Alison Conlin to review the phase III DESTINY-Breast05 trial.

Dr. Neil Iyengar shifts the discussion to the management of residual disease in HER2-positive early breast cancer, inviting Dr. Alison Conlin to review the phase III DESTINY-Breast05 trial.

Dr. Neil Iyengar continues the discussion on HER2-positive early breast cancer by exploring how the DESTINY-Breast11 findings may translate into routine clinical practice.

Dr. Neil Iyengar moderates a discussion with Dr. Alison Conlin and Dr. Kelly McCann on the design of the DESTINY-Breast11 trial and its implications for the management of HER2-positive early breast cancer.

Drs. Neil Iyengar and Kelly McCann review the phase III DESTINY-Breast11 trial, highlighting its design, patient population, and key findings demonstrating improved pathologic complete response rates with a trastuzumab deruxtecan–based neoadjuvant regimen in high-risk HER2-positive early breast cancer.

Kelly Elizabeth McCann, MD, PhD, discusses the need for breast cancer research that encompasses drugs with different payloads.

Kelly Elizabeth McCann, MD, PhD, discusses the TROP2-directed ADCs that are clinically available for metastatic TNBC management.

Kelly Elizabeth McCann, MD, PhD, discusses considerations for the sequential use of ADCs with similar payloads in HER2-positive metastatic breast cancer.

Kelly Elizabeth McCann, MD, PhD, discusses the role of post-neoadjuvant T-DXd in HER2-positive breast cancer.

Kelly Elizabeth McCann, MD, PhD, discusses the clinical utility of T-DXd followed by THP for HER2-positive early breast cancer.

Kelly Elizabeth McCann, MD, PhD, notes the role of vepdegestrant in the ESR1-mutated, ER-positive, HER2-negative advanced breast cancer treatment paradigm.

Drs Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm.

Drs McCann and Nunnery share their stories and perspectives as leading women in oncology in honor of International Women's Day.

Looking ahead, the faculty discuss unanswered questions and future data needs in the adjuvant treatment of HR-positive, HER2-negative early breast cancer.

A second case highlights a postmenopausal patient with lower nodal burden but biologically high-risk HR-positive, HER2-negative breast cancer.

Strategies to improve tolerability and adherence to abemaciclib in the adjuvant setting are examined in detail.

Strategies to improve tolerability and adherence to abemaciclib in the adjuvant setting are examined in detail.

Treatment selection between abemaciclib and ribociclib is explored for a patient with extensive nodal involvement.

Using the same high-risk patient scenario, the discussion turns to practical strategies for sequencing adjuvant endocrine therapy, ovarian function suppression, and CDK4/6 inhibition.

A premenopausal patient with stage III, node-positive HR-positive, HER2-negative breast cancer is presented to illustrate real-world risk stratification.

Long-term follow-up from the monarchE and NATALEE trials continues to influence treatment decisions in HR-positive, HER2-negative early breast cancer.

Erica Mayer, MD, and Kelly McCann, MD, outline how clinicians define high-risk hormone receptor–positive, HER2-negative early breast cancer in contemporary practice.

Panelists discuss how innovative HER2-targeted strategies and precision approaches will define the next era of breast cancer therapy.

Panelists discuss how new trial results from ASCENT-03 and TROPION-Breast02 are shaping next-generation TNBC therapies.

Panelists discuss how molecular characterization and novel agents are redefining the management of TNBC.